Kyverna Therapeutics, Inc. - Common Stock (KYTX)
3.3100
0.00 (0.00%)
Kyverna Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and related conditions
The company specializes in harnessing the power of engineered immune cells to create transformative treatment options. By utilizing advanced genetic engineering techniques, Kyverna aims to target and modify the immune system's response, thereby addressing the underlying causes of autoimmune disorders. Through its research and development initiatives, the company strives to deliver novel, effective solutions that improve patient outcomes and enhance quality of life for those affected by these challenging diseases.
Important February 7, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 30, 2025
Important February 7, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit
RADNOR, PA - January 30, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 30, 2025
Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 29, 2025
Kyverna Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - January 29, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 29, 2025
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kyverna, Five9, DMC Global, and Marqeta and Encourages Investors to Contact the Firm
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kyverna Therapeutics, Inc. (NASDAQKYTX), Five9, Inc. NASDAQ: FIVNNASDAQFIVN)(NASDAQ: BOOMNASDAQBOOM, and Marqeta, Inc. (NASDAQ:MQNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 28, 2025
KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. (KYTX) Securities Class Action Laws
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 28, 2025
KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. (KYTX) Securities Class Action Laws
RADNOR, PA - January 28, 2025 (NEWMEDIAWIRE) -The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 28, 2025
Kessler Topaz Meltzer & Check, LLP Announces KYTX DEADLINE REMINDER: Important February 7, 2025 Deadline Reminder in Kyverna Therapeutics, Inc. Securities Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · January 27, 2025
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Kyverna Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · January 27, 2025
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 26, 2025
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.
RADNOR, PA - January 26, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 26, 2025
Kyverna Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Class Action Against KYTX
SAN DIEGO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQKYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
By Robbins LLP · Via GlobeNewswire · January 24, 2025
Kyverna Therapeutics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 24, 2025
Kyverna Therapeutics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - January 24, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 24, 2025
KYTX Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (KYTX)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 22, 2025
KYTX Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (KYTX)
RADNOR, PA - January 22, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 22, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 22, 2025
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kyverna, Sun Communities, DMC Global, and Marqeta and Encourages Investors to Contact the Firm
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Kyverna Therapeutics, Inc. (NASDAQKYTX), Sun Communities NYSE: SUINYSESUI)(NASDAQ: BOOMNASDAQBOOM, and Marqeta, Inc. (NASDAQ:MQNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 21, 2025
KYTX SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (KYTX)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 21, 2025
KYTX SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (KYTX)
RADNOR, PA - January 21, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 21, 2025
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Kyverna Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · January 21, 2025
Class Action Lawsuit Reminder (KYTX): Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX ) Investors - A Securities Fraud Class Action Lawsuit Has Been Filed
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 20, 2025
Class Action Lawsuit Reminder (KYTX): Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX ) Investors - A Securities Fraud Class Action Lawsuit Has Been Filed
RADNOR, PA - January 20, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQKYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 2025.
Via TheNewswire.com · January 20, 2025
ROSEN, A LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KYTX
NEW YORK, Jan. 20, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 20, 2025
Kyverna Therapeutics, Inc. Investors: February 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 18, 2025